2005-2014
2006
Signed Research Service Contract (FTE) with AstraZeneca, Ambit Biosciences, TorreyPine Therapeutics
2007
Signed Research Service Contract (FTE) with TetraPhase Pharmaceuticals
June 27, 2008
Today SynChem announced its purchase 13,000 sq. ft. facility in Lake Zurich, Illinois for its worldwide Headquarter and US-based research and GMP laboratories.
This new purchase is one of its new development plans to continue upgrade SynChem’s capacity and also expand its business scope from research oriented to cGMP kilogram materials for clinical trials for its customers.
June 23, 2008
Today after approval from both companies’ board directors SynChem International Corporation Inc. announced merge into SynChem, Inc. starting from July 1, 2008. All SynChem International Corporation related business will be seamless flowed into SynChem’s management system.
March 18, 2008
APAC Pharma and SynChem today announced to setup their strategic alliance.
Through the combination efforts both companies will be working for bringing together with APAC Pharma’s experience on cGMP projects and SynChem’s strong capability of research oriented projects and offer their services to their clients from research medicinal chemistry projects to cGMP clinical trial projects. Dr. W. Paul Mar, SynChem’s Chairman and CEO said in the announcement, “It is great that we can get help from APAC’s strong experience in cGMP project arena and also its customer bases, SynChem also can offer our own customers from already very good medicinal chemistry service to further extend into cGMP services”. Dr. Dean Wei, APAC’s Chairman and CEO said in the announcement, “We are very happy to be able to build the strategic partnership with SynChem. We strongly believe that our customers will benefit from APAC’s cGMP manufacturing experience combined with SynChem’s medichem expertise. We look forward to a brighter future for both companies. ”
Feburary, 2009, Elk Grove Village, IL
SynChem, Inc. is proud to announce today that it finished the $1.595 million acquisition of its new headquarters and research laboratory in Elk Grove Village, Illinois, with Union National Bank in Elgin.
"We really appreciate the great financial help from Union National Bank and Small Business Growth Corporation for our new laboratory upgrade in this extremely challenge financial environment." Said Dr. W. Paul Mar, CEO of SynChem, "Also it shows the strength of SynChem's solid management in last 11 years. This investment renews our commitment to our customers that we will continue offer the highest quality services to drug discovery, biotech and pharmaceutical industries. It also renews our commitment to society that we will continue our presence in the U.S. with our effective combined business model that has served our customers well in last 11 years."
"We were pleased to assist SynChem in the acquisition of the building and with the upgrade of the labs. It will allow the business to grow and improve its current operations further. Their research and discovery is important to so many people around the world. The principals Dr. W. Paul Mar and Dr. Zhiqiang Fang were a pleasure to work with and run a great operation." said Mr. Steve Kirby, Vice President of Union National Bank in Elgin.
May 8, 2010 – Elk Grove Village, IL
SynChem, Inc. is proud to announce today that it receives an award from the American-Chinese Pharma-Biotech Association (ACPBA).
Dr. W. Paul Mar received the award for SynChem from Dr. Jinhe Li and also Dr. Mar gives a talk in the 2010 American-Chinese Pharma-Biotech Symposium at Chicago on May 2, 2010, titled as "Ups and Downs of SynChem, Surviving in the Chemistry Outsourcing Jungle", www.acbpa.org
January 8, 2010 – Elk Grove Village, IL
SynChem, Inc. is proud to announce today that it has upgraded the kilo lab in the Elk Grove Village facility.
The upgrading of the kilo lab includes installation of two 8-foot walk-in fume hoods and a sophisticated stockroom. The kilo lab currently equips with a Chemglass 30 L Jacketed Reactor with a Julabo F55 chiller system, a Chemglass 50 L Jacketed Reactor with a Julabo F55 chiller system, and a Waters HPLC system.
January 6, 2010 – Elk Grove Village, IL
SynChem, Inc. is proud to announce today that it has set up Central Analytical Chemistry Labs both in the Elk Grove Village facility and in the Shanghai branch.
The Central Analytical Chemistry lab in Elk Grove Village now equips with a Varian 300 MHz NMR, an API 150EX LC-MS, a HP G1315B DAD HPLC-DAD, and two Waters HPLC systems. The Central Analytical lab in Shanghai is equipped with a Varian 300 MHz NMR, a Fisher Thermo LC-MS, a Semi-preparative HPLC, two HPLC systems (Gilson and Shimadzu), and a CEM Explorer MicroWave Reactor. The setup of the central analytical labs will greatly improve both sites’ productivity and efficiency.
January 6, 2010 – Elk Grove Village, IL
SynChem, Inc. is proud to announce today that it has finished a half million dollars renovation of its facility and has purchased series of new equipments.
"This is our continuing efforts to upgrade our facility and equipment in this extremely challenging financial environment, I am confident that our business model is well developed and our chemists are enabled by the state-of-art equipments and facility." Said Dr. W. Paul Mar, CEO of SynChem, "also it shows the financial strength of SynChem building up in the past 12 years. This investment enables us to upgrade our research chemistry services more efficiently and broaden our service scope."
The facility upgrade involves installation of three 8-foot fume foods, two hazardous materials stockrooms, a new water treatment system for its laboratory, a new NMR room, and a new analytical chemistry laboratory. The equipment upgrade includes purchases of a Varian 300 MHz NMR, an API 150 EX LC-MS, a HP G1315B DAD HPLC-DAD, a ChemGlass 30 L Jacketed Reactor with a Julabo F55 chiller system, a Chemglass 50 L Jacketed Reactor with a Julabo F55 chiller system.
November 16, 2011 – Elk Grove Village, IL
SynChem, Inc. is proud to announce today that it raises $1.1 million capital from an investment group to setup its cGMP laboratory in Elk Grove Village, Illinois.
"This capital investment extends our current business to the upstream of much more lucrative business arena and allows us to use SynChem as business platform to continue to build our excellent business service to our customers in pharmaceutical and biotechnology companies. We at SynChem really appreciate the great financial help from the investor group headed by Henlin-biotech, LLC for our new laboratory upgrade in this extremely challenge financial environment, and we also strongly believe this will generate great return for our investors." Said Dr. W. Paul Mar, CEO of SynChem, " Again, like the investment we commit in Y2009, this investment renews our commitment to our customers that we will continue offer the highest quality services to drug discovery, biotech and pharmaceutical industries. It also renews our commitment to society that we will continue our presence in the U.S. with our effective combined business model that has served our customers well in last 14 years."
"We were pleased to assist SynChem in the setup of its GMP facility. It will not only extend its current business model but also greatly benefit Henlin-biotech’s current business model. Their research and discovery is important to our technology upgrade and modernization." said Mr. Bingye Zhang, President of Henlin-biotech in New Jersey.
Nov 09, 2011 – Elk Grove Village, IL
SynChem Appoint Dr. Ze-qi Xu to as its Chief Scientific Officer Today.
SynChem, Inc., a CRO for drug research and development services, announced today a key leadership appointment supporting the expansion of its drug discovery, research and development service capabilities. Ze-qi Xu, Ph.D., has joined SynChem, Inc. as its Chief Scientific Officer. With this appointment, SynChem seeks to further expand its services and leading scientific expertise to its customers.
Ze-Qi Xu, Ph.D.
Ze-Qi Xu, Ph.D., joins SynChem as Chief Scientific Officer. He has overall responsibility for GMP services, medicinal chemistry research, including research biology and chemistry initiatives. He will report to the Company's Chief Executive Officer.
Dr. Xu brings to SynChem more than 20 years' experience in the design, discovery and development of novel therapeutics, including an extensive background in infectious diseases. He has joined SynChem after holding increasingly senior roles at several companies, including a 9-year tenure at Advance Life Science, where he departed as Chief Scientific Officer, overseeing GMP pharmaceutical manufacturing, IND and NDA preparations and regulatory submissions with completion of two global phase III clinical trials and several phase I and II clinical trials in antibacterial, antiviral, anticancer, inflammation and respiratory disease therapies. API manufacturing of the antibacterial ketolide has passed FDA pre-approval inspection. Other past positions include Vice President of Strategic Drug Discovery and Development at MediChem Life Sciences and Adjunct Research Associate at Argonne National Laboratories. Dr. Xu is an inventor on 19 patents and has co-authored 59 peer-reviewed publications. He is a regular presenter at scientific conferences. Dr. Xu received his B.S., M.S. and Ph.D. degrees, respectively, from Jiangxi Normal University, Shanghai Medical University and Shanghai Institute of Organic Chemistry.
"We are very pleased to welcome ZQ to SynChem, and we appreciate the tremendous amount of experience he brings from biotechnology companies in bridging research and development," said W. Paul Mar, SynChem's Chief Executive Officer. "At a time when we are poised for significant advancement across multiple programs, I am confident ZQ's background and leadership will prove invaluable to SynChem as we continue to build our medicinal chemistry-center service model."
October 27, 2011 – Elk Grove Village, IL
Mr. Zhuohe Zhou, Chairman of Wuxi Fortune Pharmaceuticals and Guangdong Aimin Pharmaceuticals, visited SynChem, Inc.
Today SynChem welcome Mr. Zhuohe Zhou, Chairman of Wuxi Fortune Pharmaceuticals and Guangdong Aimin Pharmaceuticals, and Mr. Kevin Huang, Chairman and President of Truecolor Group. Mr. Zhou and Mr. Huang discussed with Drs. W. Paul Mar, Daniel Fang and ZQ Xu about the future collaboration between SynChem and Wuxi Fortune in the field of new antibiotics drug discovery and new generic drug new technology development.
"We are very pleased to have the guesses like Mr. Zhou and Mr. Huang to visit SynChem Chicago headquarters to discuss the huge opportunities that presents currently in the Chinese pharmaceutical industry and we certainly are sure we can team up with Wuxi Fortunate to join in this technology upgrade grand trends in China." said W. Paul Mar, SynChem's Chief Executive Officer. "The research capabilities and business reputation SynChem has built up since 1997 is exactly the collaboration target Wuxi is looking for in the past years and SynChem current business model will greatly benefit to both of us, especially to our technology upgrade and modernization." Said Mr. Zhou of Wuxi Fortunate Pharmaceuticals.
May 12, 2012 – Elk Grove Village, IL
The 3rd Annual Chicago Biotech-Pharma Symposium.
The 3rd Annual Chicago Biotech-Pharma Symposium was held on May 12, 2012 in the Illinois Science & Technology Park, north suburb of Chicago. The annual symposium series has been sponsored by Yaoyuan—Academy for Pharma Innovation, and organized by a group of scientists from pharmaceutical industry and academia in great Chicago area. Dr. W. Paul Mar, CEO of SynChem, Inc., chaired this year’s symposium. “Pharma R & D, A Tale of Success” was chosen as the theme of this symposium to highlight the critical path and future horizons in drug discovery and development. Six scientists who have played pivotal roles in the discovery and development of selected recently-approved drugs or associated diagnostic kit shared their exciting stories.
More than 120 scienstists and professionals from pharma industry and academia attended the conference. Multiple scientific vendors held product shows at the Symposium.
June 25, 2012 – Elk Grove Village, IL
SynChem has submitted to US PTO its first patent application for the novel ADC linker technology.
SynChem today announced that it has submitted its first patent application for the novel antibody-drug conjugate (ADC) linker technology. SynChem's technology can improve the stability of ADCs in physiology environment, decrease the aggregation and increase the solubility, challenges that many ADCs currently in development have encountered. This patent application is the direct result of SynChem internally funded research efforts.
"We are very pleased to successfully advance our internal ADC new linker research to yield fruitful results and result in the patent application for this new technology. The research team worked hard on this project and it is an important milestone in our company. Armed with this new platform technology, we can provide our customers better and more comprehensive services to solve problems faster.." W. Paul Mar, SynChem's Chief Executive Officer. "Again, this confirms our commitment to our customers that we will continue to offer the highest quality services to drug discovery, biotech and pharmaceutical industries, not only with chemistry-focused operation to complete projects on time and on budget, but also with our internally funded research to add values to our customer's program. It also strengthens our commitment to society that we will continue our presence in the U.S. which has served our customers well in last 15 years"
February 6, 2012 – Elk Grove Village, IL
Henlin Biotech management team visited SynChem, Inc.
Today SynChem welcome Mrs. Linjie Wang, Chairman of Henlin Biotech, Mr. Yinghua Wang, President of Henlin Biotech and other guests from Henlin Biotech. Mrs. Wang and Mr. Wang discussed with Drs. W. Paul Mar, Daniel Fang and ZQ Xu about the future collaboration between SynChem and Henlin in the field of chemical research and new technology development to better serve both companies’ customers. Both sides sign a memorandum of setting up a joint venture, Henlin-SynChem Inc.
"We are very pleased to setup a joint venture with Henlin Biotech so that we can utilize our own chemical research power in the technology upgrade in Chinese chemical industry. Teaming up with Henlin is one of the most important strategic for our future direction." said W. Paul Mar, SynChem's Chief Executive Officer.
"The combination of research capabilities of SynChem and manufacturing capacities of Henlin will best serve our customers and will greatly benefit to both of us, especially to our technology upgrade and modernization." Said Mrs. Wang of Henlin Biotech.
May 13, 2013– Elk Grove Village, IL
SynChem, Inc. raised its seeding round capital from a private investor to fund its proprietary new ADC linker technology research.
SynChem, Inc. announces today that it finished to raise its seeding round capital from a private investor to fund its proprietary new ADC linker technology research in Elk Grove Village, Illinois. "This new investment enables us to continue our leading position in ADC linker research and application to new successful cancer treatment, antibody drug conjugated therapy. Also this proprietary new linker technology combined with our new business model will allow SynChem not only captures the short term revenue but also midterm and long term revenues. " Said Dr. W. Paul Mar, CEO of SynChem, "Again, as in the past 16 years, we keep renew our commitment to our customers and collaborators that we will continue offer the highest quality research and services to drug discovery, biotech and pharmaceutical industries. It also renews our commitment to society that we will continue our presence in the U.S. to utilize the very best research capability shared success with collaborators well in last 16 years. "
January 01, 2013 – Elk Grove Village, IL
SynChem, Inc. licensed its new ADC linker technology patent to a European drug discovery company.
SynChem, Inc. today announced that they have signed a license agreement with a European biotechnology company. Under the terms of the agreement, SynChem will combine its expertise in synthetic organic chemistry with its proprietary antibody-drug conjugate (ADC) linker technology to design and develop novel linkers and conjugation methods for both drug payloads and antibodies. Both companies will contribute their unique and proprietary technologies to the Collaboration to develop innovative therapy for the treatment of cancer. "We are delighted for the opportunity of applying our own proprietary ADC linker technology to the development of new medications for cancer patients" said Dr. W. Paul Mar, President and CEO of SynChem, Inc.
Dec, 2014 – Elk Grove Village, IL
ILLINOIS CONTINUES TO PROMOTE LIFE SCIENCE BUSINESS OPPORTUNITIES IN EUROPE.
The Life Sciences sector has been identified as a high potential cluster in the 2014 Illinois Economic Development Plan. Illinois is already home to several of the world’s top life science companies, including; Abbott, AbbVie, Astellas, Baxter and Takeda. It is one of the top biotech States in the USA, where the industry is estimated to be worth $98.6 billion while in the more traditional medical devices sector, Illinois had the 2nd largest gain in the USA for medical device establishments.
A key part of the Economic Development Plan is to assist companies to develop new routes to export. While the United States is the world’s largest market for healthcare, its companies need to also look abroad to guarantee continued growth in this sector. In the medtech industry for example, the United States has annual sales of $139 billion. Europe, with annual sales of over $100 billion is by far the second largest market. More importantly 65% of Medtech imports coming into Europe come from the United States so for export opportunities, it is a key market to target.
Two recently completed key Trade Missions allowed Illinois companies to develop business opportunities and new markets in Europe. The first allowed nine Illinois bio companies and organisations attend the prestigious Bioeurope Conference www.edpgroup.com/bioeurope and exhbition in Frankfurt, Germany, which is the largest Biotech event in Europe with an excellent partnering platform run by EDP partnering. Using this platform effectively meant that a total of 167 focused meetings were held between the Illinois companies and European partners over the three days of the event. The feedback was extremely positive and encouraging to the point that all companies that attended would like to attend a similar event in the future.Overall the companies collectively estimate that in excess of $4million in new business will arise from their participation at this event over the next two years.
Medica, the second event on the Illinois life sciences calendar took place a week after Bioeurope. Medica is held annually in Düsseldorf, Germany and is the largest and most international world trade fair for medical devices and diagnostics. It is a particularly good show for meeting distributers, and is extremely international with 84,000 of the 130,000 visitors coming from abroad.
Seven Illinois companies exhibited on a shared Illinois stand which was busy through-out the 4 days of the show. All companies were extremely happy with both the quality and volume of the leads they obtained and estimate several million in new business arising from the promising meetings had with almost 60 new potential international distributers during the exhibition.
Nov, 2014 – Elk Grove Village, IL
SynChem, Inc. Representatives Joined in Illinois Biotech Delegate To BioEurope 2014 in Frankfurt.
As members of Illinois Biotech Delegate Dr. W. Paul Mar and Daniel Fang from SynChem joined the four days BioEurope 2014 in Frankfurt, Germany. As Europe biggest biotechnology partnering conference there are more than 3,200 participants from 1,772 companies. SynChem’s representatives meet with more than 20 potential collaborators to discuss about its own ADC linker technology and also explore potential licensing its patented technology.
